Tinodasertib
Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
43 Active assets in the Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
Cyclophosphamide Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
Imatinib The University of Hong Kong | Phase 2 | BB |
TACROLIMUS University of Michigan Rogel Cancer Center | Phase 2 | BB |
Nilotinib The University of Hong Kong | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Tinodasertib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →